argenx SE ARGX-BE:Euronext Brussels

*Data is delayed | EUR
Last | 5:38 PM CEST
299.80quote price arrow up+1.80 (+0.60%)
Volume
58,751
52 week range
201.40 - 320.00
Loading...
  • Open297.80
  • Day High301.70
  • Day Low291.30
  • Prev Close298.00
  • 52 Week High320.00
  • 52 Week High Date12/20/21
  • 52 Week Low201.40
  • 52 Week Low Date06/07/21

Key Stats

  • Market Cap16,005.35M
  • Shares Out51.67M
  • 10 Day Average Volume114,187.36
  • Dividend-
  • Dividend Yield-
  • Beta0.84
  • YTD % Change-4.92

KEY STATS

  • Open297.80
  • Day High301.70
  • Day Low291.30
  • Prev Close298.00
  • 52 Week High320.00
  • 52 Week High Date12/20/21
  • 52 Week Low201.40
  • 52 Week Low Date06/07/21
  • Market Cap16,005.35M
  • Shares Out51.67M
  • 10 Day Average Volume114,187.36
  • Dividend-
  • Dividend Yield-
  • Beta0.84
  • YTD % Change-4.92

RATIOS/PROFITABILITY

  • EPS (TTM)-10.30
  • P/E (TTM)-29.10
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On argenx SE

There is no recent news for this security.

Profile

MORE
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor...
Peter Verhaeghe
Non-Executive Independent Chairman of the Board
Tim Van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Keith Woods
Chief Operating Officer
Karl Gubitz
Chief Financial Officer
Malini Moorthy
General Counsel
Address
Willemstraat 5
Breda
4811 AH
Netherlands